JPL Wealth Management LLC Invests in Pfizer Inc. with New Shares Acquisition

JPL Wealth Management LLC has recently acquired a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, as reported in their latest 13F filing with the Securities and Exchange Commission (SEC). The firm has purchased 11,204 shares of the biopharmaceutical company, with the total investment valued at approximately $297,000.

Other institutional investors have also been active in adjusting their positions in Pfizer. Impact Capital Partners LLC acquired a new position valued at about $287,000 in the fourth quarter. Additionally, CFO4Life Group LLC increased its holdings in Pfizer by 2.2%, bringing its total to 28,725 shares worth $762,000 after obtaining an extra 614 shares last quarter. Balboa Wealth Partners also expanded its stake by 1.6%, now holding 30,678 shares valued at $814,000 after acquiring 480 shares recently. Achmea Investment Management B.V. made a significant move by acquiring a new position in Pfizer worth $2,812,000. Furthermore, Rakuten Securities Inc. enhanced its holdings by 10.2%, owning 29,424 shares valued at $781,000 after purchasing an additional 2,734 shares in the past quarter. Currently, institutional investors and hedge funds control 68.36% of Pfizer's stock.

Insider Transactions at Pfizer

In related news, Pfizer Director Ronald E. Blaylock bought 19,457 shares of the company's stock on February 13th at an average price of $25.65 per share. This transaction was valued at $499,072.05, and post-acquisition, the director holds 27,707 shares in Pfizer, which are worth approximately $710,684.55. This acquisition resulted in a significant 235.84% increase in his ownership of the stock, as disclosed in an SEC filing. Currently, corporate insiders own a modest share of Pfizer's stock, accounting for 0.06%.

Pfizer Stock Performance

Pfizer’s stock price opened at $25.73 on Thursday, with a 50-day simple moving average of $26.28 and a 200-day moving average of $27.18. The company has a quick ratio of 0.73, a current ratio of 1.00, and a debt-to-equity ratio of 0.63. Over the past year, Pfizer has seen a 52-week low of $24.48 and a high of $31.54. The company's market capitalization stands at $145.79 billion, with a price-to-earnings ratio of 18.24 and a PEG ratio of 0.64.

Recently, Pfizer reported its earnings results for the last quarter on February 4th. The company achieved earnings of $0.63 per share, surpassing the expected consensus of $0.48 by $0.15. Revenue for the quarter was $17.76 billion, exceeding analyst expectations of $17.26 billion. Pfizer also noted a net margin of 12.62% and a return on equity of 19.47%, marking a year-over-year revenue increase of 24.7%. Analysts predict that Pfizer will report an EPS of 2.95 for the current fiscal year.

Wall Street Analyst Opinions

In recent evaluations, several analysts have provided insights on Pfizer's stock performance. UBS Group revised their target price down from $31.00 to $29.00, giving the stock a "neutral" rating. Wolfe Research initiated coverage on Pfizer with an "underperform" rating and a target price of $25.00. Truist Financial also lowered their target price to $32.00 while maintaining a "buy" rating. Bank of America reaffirmed a "neutral" stance with a target price set at $29.00, while Guggenheim reiterated a "buy" rating. Currently, one analyst has assigned a sell rating, eight have given a hold rating, six issued a buy rating, and three designated it as a strong buy. According to MarketBeat.com, Pfizer's stock has an average rating of "Moderate Buy" with an average price target of $31.92.

About Pfizer Inc.

Pfizer Inc. is actively engaged in discovering, developing, manufacturing, marketing, distributing, and selling a range of biopharmaceutical products across the globe, including in the United States and Europe. The company provides various medicines and vaccines targeting multiple therapeutic areas such as cardiovascular, migraine, women's health, and infectious diseases, using established brands like Eliquis, Nurtec ODT/Vydura, and Comirnaty.

investment, shares, stocks